Cellectis

CLLSPhase 2

Paris, FranceFounded 1999cellectis.com

Cellectis is a French-American biotech with 25 years of expertise in gene editing, focused on developing next-generation, 'off-the-shelf' CAR T-cell therapies to address significant unmet needs in oncology. The company's core platform combines its flagship TALEN® technology for ultra-precise genome editing with its PulseAgile electroporation system for efficient cellular engineering. With a robust pipeline of allogeneic CAR T candidates and strategic global partnerships with companies like Allogene, Servier, and AstraZeneca, Cellectis aims to transform cancer treatment by making cell therapies more accessible and scalable.

Market Cap

$242.5M

Founded

1999

CLLS · Stock Price

USD 3.341.05 (-23.92%)

Historical price data

AI Company Overview

Technology Platform

Proprietary TALEN® gene-editing technology for precise DNA modification and PulseAgile® electroporation system for efficient cellular engineering, enabling the development of off-the-shelf allogeneic CAR T-cell therapies.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
UCART22 + CLLS52	B-cell Acute Lymphoblastic Leukemia	Phase 1/2
UCART20x22 + CLLS52	B-cell Non-Hodgkin Lymphoma (B-NHL)	Phase 1/2
UCART123	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	Phase 1
UCART123v1.2	Relapsed/Refractory Acute Myeloid Leukemia	Phase 1
UCART123	Acute Myeloid Leukaemia	Phase 1

Funding History

Total raised: $298M

PIPE$228MPfizerSep 15, 2015

IPO$60MUndisclosedMar 20, 2015

Series A$10MUndisclosedJun 15, 2000

Opportunities

The primary growth opportunity is the successful development and commercialization of lasme-cel, which could capture a significant portion of the ~$700 million peak sales opportunity in r/r B-ALL.

Beyond this, the validated TALEN® platform can be leveraged to develop a pipeline of additional allogeneic UCARTs for other hematologic and solid tumors, and the technology has potential applications in non-viral gene therapy and base editing for genetic diseases.

Risk Factors

Key risks include clinical failure of the lead asset lasme-cel, regulatory hurdles for novel allogeneic therapies, significant cash burn requiring future dilutive financing, intense competition from CRISPR-based allogeneic CAR-T companies, and challenges in scaling manufacturing for commercial supply.

Competitive Landscape

Cellectis competes in the allogeneic CAR-T space against well-funded companies like Allogene Therapeutics, CRISPR Therapeutics, and Precision BioSciences. Its differentiation is based on the perceived precision and safety of its proprietary TALEN® gene-editing platform versus widely used CRISPR systems, and its integrated control of both editing and manufacturing technology.

Publications

Patents

Pipeline